Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline

BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)‐4/IL‐13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add‐on dupilumab 200/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodila...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourdin, Arnaud, Papi, Alberto A., Corren, Jonathan, Virchow, J. Christian, Rice, Megan S., Deniz, Yamo, Djandji, Michel, Rowe, Paul, Pavord, Ian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820970/
https://www.ncbi.nlm.nih.gov/pubmed/33010038
http://dx.doi.org/10.1111/all.14611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7820970/
https://www.ncbi.nlm.nih.gov/pubmed/33010038
http://dx.doi.org/10.1111/all.14611

Ejemplares similares